Research graph
References from Switching standard dosed intravenous to subcutaneous infliximab leads to similar drug exposure in inflammatory bowel disease patients independent of concomitant immunosuppressants (SHUFFLE study). Local targets link to admitted publications; unresolved targets remain external evidence.
10.1007/s40262‐018‐0639‐4
10.1007/s40262‐018‐0639‐4 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Immunogenicity and efficacy of subcutaneous infliximab monotherapy vs combination therapy in inflammatory bowel disease: a systematic review and meta‐analysis
10.1016/j.cgh.2025.03.021 · 2026 · External reference
Unresolved reference
External reference
Bayesian estimation of pharmacokinetic parameters: an important component in the teaching of clinical pharmacokinetics and therapeutic drug monitoring
10.4103/1735-5362.301335 · 2020 · External reference
10.1016/j.cgh.2018.09.033
10.1016/j.cgh.2018.09.033 · External reference
Combination therapy with immunomodulators improves the pharmacokinetics of infliximab but not vedolizumab or ustekinumab
2022 · External reference
10.1053/j.gastro.2013.10.052
10.1053/j.gastro.2013.10.052 · External reference
10.1056/nejmoa0904492
10.1056/nejmoa0904492 · External reference
10.1136/gutjnl‐2016‐313071
10.1136/gutjnl‐2016‐313071 · External reference
A simple index of Crohn's disease activity
10.1016/s0140-6736(80)92767-1 · 1980 · External reference
10.1002/ibd.20520
10.1002/ibd.20520 · External reference
10.1037/1082‐989x.7.2.147
10.1037/1082‐989x.7.2.147 · External reference
Development and validation of a remote monitoring tool for assessment of mild, moderate, and severe infections in inflammatory bowel disease
10.1093/ecco-jcc/jjad023 · 2023 · External reference
Drug‐tolerant anti‐infliximab antibody assay
2017 · External reference
10.1093/clinchem/44.3.551
10.1093/clinchem/44.3.551 · External reference
Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn's disease and ulcerative colitis
10.1111/apt.16609 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
2015 · External reference
10.3390/jcm11206173
10.3390/jcm11206173 · External reference
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within a 14‐day treatment cycle in Crohn's disease
10.1111/apt.16852 · 2022 · External reference
10.1093/ecco‐jcc/jjac053
10.1093/ecco‐jcc/jjac053 · External reference
Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial
10.1007/s40261-023-01252-z · 2023 · External reference
10.1111/apt.70267
10.1111/apt.70267 · External reference
10.1097/meg.0000000000002835
10.1097/meg.0000000000002835 · External reference
10.1093/ibd/izaf038
10.1093/ibd/izaf038 · External reference
10.1007/s13318‐025‐00959‐y
10.1007/s13318‐025‐00959‐y · External reference
10.1093/ecco‐jcc/jjy003
10.1093/ecco‐jcc/jjy003 · External reference
10.1177/10600280231170650
10.1177/10600280231170650 · External reference
10.1007/s40259‐020‐00465‐4
10.1007/s40259‐020‐00465‐4 · External reference
10.3389/fimmu.2020.01951
10.3389/fimmu.2020.01951 · External reference
10.1016/j.xphs.2017.05.030
10.1016/j.xphs.2017.05.030 · External reference
10.1002/ibd.20301
10.1002/ibd.20301 · External reference
10.1097/00005176‐199904001‐00003
10.1097/00005176‐199904001‐00003 · External reference
10.1002/ibd.20301
10.1002/ibd.20301 · ExternalCitation · doi-reference
10.1002/ibd.20520
10.1002/ibd.20520 · ExternalCitation · doi-reference
10.1007/s13318‐025‐00959‐y
10.1007/s13318‐025‐00959‐y · ExternalCitation · doi-reference
10.1007/s40259‐020‐00465‐4
10.1007/s40259‐020‐00465‐4 · ExternalCitation · doi-reference
Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial
10.1007/s40261-023-01252-z · ExternalCitation · doi-reference
10.1007/s40262‐018‐0639‐4
10.1007/s40262‐018‐0639‐4 · ExternalCitation · doi-reference
10.1016/j.cgh.2018.09.033
10.1016/j.cgh.2018.09.033 · ExternalCitation · doi-reference
Immunogenicity and efficacy of subcutaneous infliximab monotherapy vs combination therapy in inflammatory bowel disease: a systematic review and meta‐analysis
10.1016/j.cgh.2025.03.021 · ExternalCitation · doi-reference
10.1016/j.xphs.2017.05.030
10.1016/j.xphs.2017.05.030 · ExternalCitation · doi-reference
A simple index of Crohn's disease activity
10.1016/s0140-6736(80)92767-1 · ExternalCitation · doi-reference
10.1037/1082‐989x.7.2.147
10.1037/1082‐989x.7.2.147 · ExternalCitation · doi-reference
10.1053/j.gastro.2013.10.052
10.1053/j.gastro.2013.10.052 · ExternalCitation · doi-reference
10.1056/nejmoa0904492
10.1056/nejmoa0904492 · ExternalCitation · doi-reference
10.1093/clinchem/44.3.551
10.1093/clinchem/44.3.551 · ExternalCitation · doi-reference
Development and validation of a remote monitoring tool for assessment of mild, moderate, and severe infections in inflammatory bowel disease
10.1093/ecco-jcc/jjad023 · ExternalCitation · doi-reference
10.1093/ecco‐jcc/jjac053
10.1093/ecco‐jcc/jjac053 · ExternalCitation · doi-reference
10.1093/ecco‐jcc/jjy003
10.1093/ecco‐jcc/jjy003 · ExternalCitation · doi-reference
10.1093/ibd/izaf038
10.1093/ibd/izaf038 · ExternalCitation · doi-reference
10.1097/00005176‐199904001‐00003
10.1097/00005176‐199904001‐00003 · ExternalCitation · doi-reference
10.1097/meg.0000000000002835
10.1097/meg.0000000000002835 · ExternalCitation · doi-reference
Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn's disease and ulcerative colitis
10.1111/apt.16609 · ExternalCitation · doi-reference
Subcutaneous injection of infliximab CT‐P13 results in stable drug levels within a 14‐day treatment cycle in Crohn's disease
10.1111/apt.16852 · ExternalCitation · doi-reference
10.1111/apt.70267
10.1111/apt.70267 · ExternalCitation · doi-reference
10.1136/gutjnl‐2016‐313071
10.1136/gutjnl‐2016‐313071 · ExternalCitation · doi-reference
10.1177/10600280231170650
10.1177/10600280231170650 · ExternalCitation · doi-reference
10.3389/fimmu.2020.01951
10.3389/fimmu.2020.01951 · ExternalCitation · doi-reference
10.3390/jcm11206173
10.3390/jcm11206173 · ExternalCitation · doi-reference
Bayesian estimation of pharmacokinetic parameters: an important component in the teaching of clinical pharmacokinetics and therapeutic drug monitoring
10.4103/1735-5362.301335 · ExternalCitation · doi-reference
